Ce guide rassemble des documents existants liés à la santé mentale et au soutien psychosocial (MHPSS) relatifs à la crise du COVID-19, ainsi que d'autres ressources applicables au contexte. Il est divisé en différentes sections en fonction des « espaces de nouvelle vulnérabilité » inhéren...ts à certains programmes de l'OIM, bien que beaucoup d'entre eux soient applicables à d'autres domaines. Ce guide couvre à la fois l'intégration de la SMSPS et des actions spécifiques.
Les responsables SMSPS trouveront également des conseils sur la façon de résoudre les problèmes moins techniques et plus managériaux et programmatiques liés à la pandémie, y compris la redéfinition des programmes, la capacité de crise et comment gérer les demandes de soutien des collègues des mêmes missions.
more
Resumo: o que é esta orientação dinâmica?
Pergunta clínica: qual é o papel dos medicamentos na prevenção da COVID-19?
Público-alvo: o público-alvo são os médicos e os tomadores de decisão na área da saúde.
Prática atual: o uso atual de medicamentos para prevenção da COVID-19 é ...variável, refletindo uma incerteza em grande escala. Numerosos estudos clínicos randomizados de muitos medicamentos estão em andamento para orientar melhor a prática. Esta primeira versão de Medicamentos para prevenção da COVID-19: Orientação dinâmica da OMS contém novas
informações e uma recomendação sobre a hidroxicloroquina. (1) Segue-se a publicação de seis estudos sintetizados em uma meta-análise dinâmica de rede (NMA).
more
Findings, interpretations and conclusions
expressed in this document are based on infor-
mation gathered by GIZ and its consultants,
partners and contributors from reliable sources.
Clinical guideline for paediatric care of tuberculosis and TB-HIV co-infection
Guidelines for Diagnosis and Management of Lung Cancer in Indonesia
Notable progress has also been made on other key health indicators such as reducing maternal, infant and child deaths and malnutrition, increasing immunization coverage, eliminating infectious diseases such as polio and reducing the incidence of malaria, tuberculosis and diarrhoeal diseases.
But ...despite such substantial progress, the country now faces new and emerging new challenges such as the rising burden of noncommunicable diseases, increased risks associated with disasters, environmental threats and health emergencies during disease outbreaks including the COVID-19 pandemic that is a serious public health threat to Bangladesh. To establish a resilience system for future potential pandemics, the national capacity for emergency preparedness and early response to health emergencies needs to be bolstered considerably.
more
Washington, D.C., ÉUA, du 26 au 30 septembre 2016
Point 4.10 de l’ordre du jour provisoire
CD55/14 8 juillet 2016
Original : anglais
In the framework of the United Nations Sustainable Development Goals Issue-based Coalition on Health and Well-being for All at All Ages in Europe and Central Asia
This article was published on December 10, 2020, and updated on December 16, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2034577
sthma prevalence is increasing worldwide, and surveys indicate that most patients in developed and developing countries, including South Africa, do not receive optimal care and are therefore not well controlled. Standard management guidelines adapted to in-country realities are important to support ...optimal care. The South African Thoracic Society (SATS) first published a guideline for the management of chronic persistent asthma in 1992, which has subsequently been revised several times.
The main aim of the present document was to revise and update SATS’ statement on the suggested management of chronic asthma, based on the need to promote optimal care and control of asthma, together with the incorporation of new concepts and drug developments. This revised document reinforces optimal care and incorporates the following primary objectives to achieve the recent advances in asthma care:
• continued emphasis on the use of inhaled corticosteroids (ICS) as the foundation of asthma treatment
• to reduce the reliance on short-acting beta-2 agonist (SABA) monotherapy for asthma symptoms
• to incorporate the evidence and strategy for the use of the combination of an ICS and formoterol for acute symptom relief (instead of a SABA)
• to incorporate the evidence and strategy for the use of as-needed ICS-long-acting beta agonists (LABA) for patients with infrequent symptoms or ‘mild’ asthma
• to incorporate the evidence and strategy for the use of a long-acting muscarinic antagonist (LAMA) in combination with ICS-LABA; and
• to incorporate the evidence and strategy for the use of and management with a biologic therapy in severe asthma.
more
Zugang zur Gesundheitsversorgung für EU-Bürgerinnen und EU-Bürger – Handreichung zu den rechtlichen Grundlagen – Siehe vor allem das Kapitel zum Thema "Fehlender Krankenversicherungsschutz", Seite 11-15:
Was ist zu tun, wenn es weder einen gesetzlichen Krankenversicherungsschutz in Deutsch...land gibt, noch einen mitgebrachten aus dem Herkunftsland?
more